Our brochure provides a comprehensive technical overview of our DN model portfolio.

This promotional material will provide you with a detailed presentation of:

• A Diverse Model Portfolio: Covering type 1 and type 2 DN modeling services across multiple species, including mice, rats, and non-human primates. Our modeling strategies range from pharmacological induction (STZ), genetically modified models, diet-induced models, to combined modeling approaches that better recapitulate the progressive nature of human DN.
• Complete Evaluation Criteria: A clear framework for DN assessment in mice, including key endpoints such as fasting blood glucose, urinary albumin-to-creatinine ratio (UACR), and comprehensive histopathological evaluation.
• Case Study Data: A detailed case study of the STZ combined with HFD-induced diabetic nephropathy mouse model is presented, including animal grouping, study protocol, and key readout results such as blood glucose levels, urinary albumin-to-creatinine ratio (UACR), and glomerular sclerosis grade.
• Supporting Platforms: Our brochure also highlights our in vitro platforms, histology slide preparation, staining (H&E, PAS, Masson), imaging, and animal facilities.

Our validated diabetic nephropathy models provide a reliable experimental platform for evaluating clients' drug candidates.

Download the brochure to access complete model parameters, case datasets, and histopathological images. Then contact us to discuss how these DN models can be tailored to your drug development program.

You might be interested in...